Background: Heartburn occurs predominantly in the upper gastrointestinal tract and is associated with gastroesophageal reflux disease (GERD) and gastritis. Omeprazole is the most prescribed proton pump inhibitor class of medication to treat heartburn related clinical conditions. To compare the efficacy of omeprazole 40 mg (as a total daily dose) and 20 mg using patient-reported outcome measures (PROMs) in patients with heartburn due to various aetiologies like non-erosive reflux disease, GERD, gastritis, dyspepsia, functional heartburn, gastro-duodenal ulcer.Methods: Naïve patients presenting heartburn symptoms were treated with omeprazole. PROMs were assessed based on short-form-leeds dyspepsia questionnaires (SF-LDQ), work productivity activity impairment (WPAI), relief obtained using medication and, treatment satisfactory questionnaires (TSQ).Results: A total of 18,724 patients with heartburn (GERD and gastritis; n=10,509) were treated with omeprazole (Dr. Reddy’s omeprazole [DO]/generic omeprazole [GO]/branded omeprazole [BO]) 40 mg (as a total daily dose) and 20 mg. Statistical comparative analysis showed significant improvement with omeprazole 40 mg (as a total daily dose) compared to omeprazole 20 mg in SF-LDQ, relief obtained using medication among patients with heartburn. DO 20 mg showed a greater improvement under the ‘a lot’ and ‘complete’ relief category.Conclusions: Omeprazole 40 mg (as a total daily dose) presented better efficacy as compared to omeprazole 20 mg in patient reported outcomes. This study highlights omeprazole 40 mg as the preferred intervention for improving PROMs and quality of life in the treatment of heartburn related clinical conditions.
Primary hemochromatosis refers to a congenital autosomal recessive disease associated with a mutation of the homeostatic iron regulator (HFE gene), whose pathogenetic mechanism is increased iron absorption in the intestines, which leads to excessive accumulation of iron in organs and tissues, mainly in the liver, pancreas, heart, pituitary gland, testicles. The consequence of the disease is the development of fibrosis and insufficiency of these organs. Genotyping of HFE gene mutations is the main method of hemochromatosis verification. The presence of the C282Y/C282Y genotype in combination with iron overload manifestations is a diagnostic criterion of the disease. The basic treatment of patients with hemochromatosis is phlebotomy, which can be combined with the prescription of iron chelators, symptomatic therapy.A clinical case of primary hemochromatosis in a 48-year-old man is of interest due to long-term persistence of certain symptomatic manifestations of hemochromatosis and verification of the disease only after decompensation of a cardiovascular pathology and magnetic resonance imaging (MRI) of the thoracic cavity. After obtaining the final diagnosis and treatment, the patient showed positive dynamics of clinical symptoms, laboratory and instrumental data.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.